152 related articles for article (PubMed ID: 22621180)
21. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
[TBL] [Abstract][Full Text] [Related]
22. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
[TBL] [Abstract][Full Text] [Related]
23. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
[TBL] [Abstract][Full Text] [Related]
24. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
Carruthers A; Carruthers J; Flynn TC; Leong MS
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
[TBL] [Abstract][Full Text] [Related]
25. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
Carruthers A; Carruthers J; Said S
Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
[TBL] [Abstract][Full Text] [Related]
26. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines.
Beer KR; Boyd C; Patel RK; Bowen B; James SP; Brin MF
J Drugs Dermatol; 2011 Jan; 10(1):39-44. PubMed ID: 21197522
[TBL] [Abstract][Full Text] [Related]
27. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
[TBL] [Abstract][Full Text] [Related]
28. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
[TBL] [Abstract][Full Text] [Related]
30. Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.
Hexsel D; Brum C; Porto MD; Soirefmann M; Siega C; Schilling-Souza J; Rodrigues TC
J Drugs Dermatol; 2013 Dec; 12(12):1356-62. PubMed ID: 24301236
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
Goldman ND; Dorton LH; Marcum KK; Gilbert RM; Sandoval LF
J Cosmet Dermatol; 2014 Sep; 13(3):224-31. PubMed ID: 25196690
[TBL] [Abstract][Full Text] [Related]
32. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG.
Schnitzler A; Genet F; Durand MC; Roche N; Bensmail D; Chartier-Kastler E; Denys P
Neurourol Urodyn; 2011 Nov; 30(8):1533-7. PubMed ID: 21661038
[TBL] [Abstract][Full Text] [Related]
33. Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines.
Joseph JH; Maas C; Palm MD; Lain E; Glaser DA; Bruce S; Yoelin S; Cox SE; Fagien S; Sangha S; Maltman J; Lei X; Brin MF
Aesthet Surg J; 2022 Oct; 42(11):1318-1327. PubMed ID: 35704394
[TBL] [Abstract][Full Text] [Related]
34. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
[TBL] [Abstract][Full Text] [Related]
35. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
Monheit G; Carruthers A; Brandt F; Rand R
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
[TBL] [Abstract][Full Text] [Related]
37. Muscle atrophy beyond the clinical effect after a single dose of OnabotulinumtoxinA injected in the procerus muscle: a study with magnetic resonance imaging.
Koerte IK; Schroeder AS; Fietzek UM; Borggraefe I; Kerscher M; Berweck S; Reiser M; Ertl-Wagner B; Heinen F
Dermatol Surg; 2013 May; 39(5):761-5. PubMed ID: 23379599
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines.
Palm MD; Few J; Patel T; Safa M; Drinkwater A; Mao C; Garcia JK
Dermatol Surg; 2020 May; 46(5):653-661. PubMed ID: 31625954
[TBL] [Abstract][Full Text] [Related]
39. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study.
Oliveira de Morais O; Matos Reis-Filho E; Vilela Pereira L; Martins Gomes C; Alves G
J Drugs Dermatol; 2012 Feb; 11(2):216-9. PubMed ID: 22270205
[TBL] [Abstract][Full Text] [Related]
40. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo.
Carruthers J; Solish N; Humphrey S; Rosen N; Muhn C; Bertucci V; Swift A; Metelitsa A; Rubio RG; Waugh J; Quiring J; Shears G; Carruthers A
Dermatol Surg; 2017 Nov; 43(11):1321-1331. PubMed ID: 28614091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
